Surufatinib Approved in China For the Treatment of Pancreatic Neuroendocrine Tumors
https://unsplash.com/photos/_jbClosDsD4

Surufatinib Approved in China For the Treatment of Pancreatic Neuroendocrine Tumors

The National Medical Products Administration (NMPA) of China has recently approved surufatinib for drug registration for the treatment of advanced pancreatic neuroendocrine tumors (pNETs). HUTCHMED Limited recently announced the news,…

Continue Reading Surufatinib Approved in China For the Treatment of Pancreatic Neuroendocrine Tumors
Four New Rare Disease Studies Receive $19 Million in Funding
source: pixabay.com

Four New Rare Disease Studies Receive $19 Million in Funding

The Patient-Centered Outcomes Research Institute (PCORI) has announced that it will be contributing funding for four new studies focused on four different rare diseases. The funding will top out at…

Continue Reading Four New Rare Disease Studies Receive $19 Million in Funding
Neuroendocrine Tumors Trial Results Demonstrate Preserved Quality of Life With Doubled Treatment Dose
source: pixabay.com

Neuroendocrine Tumors Trial Results Demonstrate Preserved Quality of Life With Doubled Treatment Dose

According to a story from businesswire.com, the biopharmaceutical company Ipsen recently presented a total of 9 study abstracts at the recent 18th annual conference of the European Neuroendocrine Tumor Society…

Continue Reading Neuroendocrine Tumors Trial Results Demonstrate Preserved Quality of Life With Doubled Treatment Dose
FDA Approves PRRT to Treat Neuroendocrine Tumors
source: pixabay.com

FDA Approves PRRT to Treat Neuroendocrine Tumors

  Patients with inoperable or metastasized neuroendocrine tumors (NETs) may now benefit from recently FDA approved peptide receptor radionuclide therapy (PRRT) according to a recent article in MedPage Today. The…

Continue Reading FDA Approves PRRT to Treat Neuroendocrine Tumors
FDA Grants Orphan Drug Designation for Treatment of Pancreatic Neuroendocrine Tumors
source: pixabay.com

FDA Grants Orphan Drug Designation for Treatment of Pancreatic Neuroendocrine Tumors

  Surufatinib was recently granted Orphan Drug designation by the FDA. This drug was made for the treatment of pancreatic neuroendocrine tumors (PanNETs). It was created by Hutchison China MediTech…

Continue Reading FDA Grants Orphan Drug Designation for Treatment of Pancreatic Neuroendocrine Tumors
Phase 1 Trial of Experimental Treatment for Neuroendocrine Tumors Begins
bdyczewski / Pixabay

Phase 1 Trial of Experimental Treatment for Neuroendocrine Tumors Begins

According to a story from Central Charts, the drug developer Crinetics Pharmaceuticals, Inc. recently issued an announcement revealing that the company has begun the initialization of a Phase 1 clinical…

Continue Reading Phase 1 Trial of Experimental Treatment for Neuroendocrine Tumors Begins
Study Reveals Combination Therapy for Aggressive, Cancerous Neuroendocrine Tumors
Bru-nO / Pixabay

Study Reveals Combination Therapy for Aggressive, Cancerous Neuroendocrine Tumors

According to a story from EurekAlert!, a recent research study has found that a two part immunotherapy combination treatment has the potential to be a useful treatment for high-grade neuroendocrine…

Continue Reading Study Reveals Combination Therapy for Aggressive, Cancerous Neuroendocrine Tumors